Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Casuistry
Chronic eosinophilic pneumonia in RA
- Case Study: Secondary Pseudohypoaldosteronism
Severe electrolyte imbalances and nonspecific symptoms in an infant
- CKD and High Blood Pressure
Keeping an Eye on Bidirectional Interactions
- Molecular Classification, FIGO 2023, and Chemoimmunotherapy
Endometrial carcinoma
- Psoriatic Arthritis
Older patients at risk for tachyarrhythmias
- Genetic Kidney Disease: DOUBLE PROTECT Alport
The SGLT-2 inhibitor dapagliflozin as an add-on to RAS blockade
- Case Study: Cystic Fibrosis in Adults
Recurrent Pneumonia as a Manifestation of Cystic Fibrosis
- Long COVID/Fatigue Clinic